新型抗凝血药物能全面代替华法林吗?

被引:8
作者
饶志方
王婉钢
机构
[1] 华润武钢总医院
关键词
达比加群; 利伐沙班; 阿哌沙班; 依度沙班; 华法林;
D O I
暂无
中图分类号
R972 [心血管系统药物];
学科分类号
1007 ;
摘要
查阅国内外关于新型抗凝血药物、华法林在预防和治疗血栓方面的最新文献,结果表明新型抗凝血药物对于中重度肝肾功能损伤的患者需要禁用、或者需要调整剂量、没有拮抗药、没有方便的监测血药浓度的手段,从而限制其使用;华法林在以下几类患者的治疗中有优势:1更换机械瓣膜;2肌酐清除率<25 ml·min-1;3瓣膜病变;4体质量大于120kg或者小于60kg;5肝炎活动期。因此,新型抗凝血药物不能全面代替华法林。
引用
收藏
页码:1211 / 1212
页数:2
相关论文
共 11 条
[1]   心房颤动口服抗凝药进展 [J].
钱方毅 .
中国循环杂志, 2014, 29 (06) :473-475
[2]   血液透析患者肝素及低分子肝素钠过敏1例 [J].
朱戈丽 ;
汪贤聪 ;
林玲 ;
夏悦 .
中国药师, 2014, 17 (03) :465-466
[3]   1例华法林相关性脑出血患者的药学监护 [J].
刘舒扬 .
中国药师, 2014, 17 (01) :137-139
[4]  
新型口服抗凝药物临床研究进展[J]. 高润霖. 中华医学杂志. 2013 (31)
[5]   Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation [J].
Pokorney, Sean D. ;
Sherwood, Matthew W. ;
Becker, Richard C. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (02) :163-174
[6]  
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct F actor X a inhibitor[J] . Dagmar Kubitza,Angelika Roth,Michael Becka,Abir Alatrach,Atef Halabi,Holger Hinrichsen,Wolfgang Mueck. Br J Clin Pharmacol . 2013 (1)
[7]  
Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment[J] . Jochen Graff,Sebastian Harder. Clinical Pharmacokinetics . 2013 (4)
[8]  
Monitoring plasma levels of factor Xa inhibitors: how, why and when?[J] . Samama,Amiral,Guinet,Flem,Seghatchian. Expert Review of Hematology . 2013 (2)
[9]  
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation[J] . Corey S. Miller,Sonia M. Grandi,Avi Shimony,Kristian B. Filion,Mark J. Eisenberg. The American Journal of Cardiology . 2012 (3)
[10]  
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor[J] . DagmarKubitza,MichaelBecka,WolfgangMueck,AtefHalabi,HaidarMaatouk,NorbertKlause,VolkmarLufft,Dominic D.Wand,ThomasPhilipp,HeikeBruck. British Journal of Clinical Pharmacology . 2010 (5)